The Bionomics Ltd (ASX: BNO) share price shot up 41% today after the biotechnology researcher announced its PTSD drug labelled BNC210 had delivered positive results from a clinical trial. In five healthy male volunteers it was found that the drug achieved the “blood levels predicted as necessary to meet the primary endpoints for effectiveness for treating Post-Traumatic Stress Disorder (PTSD) patients in future clinical trials.”
While a 41% gain might sound impressive it’s worth noting the penny stock is only 2.4 cents higher to 8.2 cents on volume around 51.3 million shares traded. In other words only around $4.5 million worth of stock has been traded.
Earlier in September the company also announced it had met with the US healthcare regulator the FDA to discuss how to design a potential Phase II trial for the PTSD drug. It also boasted that it had applied for a ‘fast track’ designation status for the application.
It’s worth noting Phase II trials themselves are generally quite early stage and partly to just demonstrate safety ahead of what is nearly always the largest and most expensive Phase III trial designed to actually test the clinical efficacy of a drug.
As such it seems Bionomics has a long road ahead of it yet and I would not suggest buying shares.
Our Motley Fool experts have just released a brand new FREE report, detailing 5 dirt cheap shares that you can buy today.
One stock is an Australian internet darling with a rock solid reputation and an exciting new business line that promises years (or even decades) of growth… while trading at an ultra-low price…
Another is a diversified conglomerate trading near a 52-week low all while offering a 2.8% fully franked yield...
Plus 3 more cheap bets that could position you to profit over the next 12 months!
See for yourself now. Simply click the link below to scoop up your FREE copy and discover all 5 shares. But you will want to hurry – this free report is available for a brief time only.
You can find Tom on Twitter @tommyr345
The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.